Free light chains (FLC), kappa (κ) lambda (λ), are produced by plasma cells and known to be an important marker in patients with Multiple Myeloma and AL Amyloidosis. The precursor condition to Multiple Myeloma is called Monoclonal Gammopathy of Undetermined Significance (MGUS) and although these individuals are not immediately treated, they are closely monitored due to their risk of progression to Multiple Myeloma1.
This webinar is designed for laboratorians and clinicians who are interested in learning more about the clinical and laboratory investigation of multiple myeloma and MGUS, and the potential clinical usage of the N Latex FLC assay in evaluation of MGUS.
- Define multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS)
- Describe the clinical criteria used to define multiple myeloma
- Describe the use of free light chains in the evaluation of MGUS
Dr. John Mitsios, Ph.D.
Senior Clinical Consultant, Siemens Healthineers
Dr. Mitsios graduated from the University of Ioannina, Greece with a PhD in Chemistry. Upon completion of his doctoral thesis, he completed a post-doctoral fellowship at the University of California, San Diego under the mentorship of Dr. Sanford J. Shattil. Dr. Mitsios then transitioned into the world of Clinical Chemistry and completed a fellowship at Washington University in St. Louis, MO.
His primary research interest has been in coagulation, with an emphasis on platelet function and biology. Recently Dr. Mitsios joined Siemens-Healthineers as a clinical consultant as part of the Scientific and Clinical Affairs team. Dr. Mitsios has co-authored 20 peer-reviewed articles and three book chapters.